Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

End-of-day quote. End-of-day quote  - 05/22
7.68 USD   +7.56%
09/15 WHAT HAPPENED T : LXRX) Telotristat Etiprate?
09/12 DELVING INTO TH : LXRX) Data
08/04 LEXICON PHARMAC : reports 2Q loss
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 84,3 M
EBIT 2016 -151 M
Net income 2016 -153 M
Debt 2016 -
Yield 2016 -
Sales 2017 106 M
EBIT 2017 -157 M
Net income 2017 -158 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 23,0x
Capi. / Sales2017 18,2x
Capitalization 1 935 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. engages in discovery and development of breakthrough treatments for human disease.The company primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
09/15 LEXICON PHARMACEUTICALS : To Present At The Bank Of America Merrill Lynch Global..
09/15 LEXICON PHARMACEUTICALS : Reports Positive Top-Line Results In Pivotal Phase 3 S..
09/15 WHAT HAPPENED TO FDA REVIEW OF LEXIC : LXRX) Telotristat Etiprate?
09/12 DELVING INTO THE LEXICON PHARMACEUTI : LXRX) Data
08/18 LEXICON PHARMACEUTICALS : To Present At The 2016 Wedbush PacGrow Healthcare Conf..
08/11 LEXICON PHARMACEUTICALS : To Report Second Quarter 2016 Financial Results On Aug..
08/05 LEXICON PHARMACEUTICALS : Assigned Patent
08/04 LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
08/04 LEXICON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
08/04 LEXICON PHARMACEUTICALS : reports 2Q loss
More news
Sector news : Bio Therapeutic Drugs
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More
2015 Lexicon Undervalued As It Approaches A Major Event
2015 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning..
2015 Lexicon Pharmaceuticals EPS in-line, beats on revenue
2015 Lexicon Pharmaceuticals - A Diamond In The Rough?
Advertisement
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 22,8 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
John Northcott VP-Marketing, Commercial Strategy & Operations
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICAL..12.10%1 935
AMGEN, INC.7.68%130 813
GILEAD SCIENCES, INC.-19.59%107 381
CELGENE CORPORATION-8.63%84 821
REGENERON PHARMACEUTIC..-24.40%43 212
VERTEX PHARMACEUTICALS..-27.97%22 456
More Results